5 trade signals across stocks, crypto & prediction markets. Entry/exit targets on every idea. This is what subscribers get every Sunday.
The S&P 500 broke below its 200-day moving average this week for the first time in 214 sessions, closing near 5,558 — its fourth consecutive weekly decline. The technical breakdown reflects mounting uncertainty as the Fed held rates at 3.50–3.75% with the updated dot plot signaling fewer cuts than markets had priced in. Core PCE projections rose to 2.7% for the year, and January PPI surprised hot at +0.5% headline and +0.8% core.
The geopolitical backdrop is the dominant macro risk. Brent crude pushed above $103/bbl on Strait of Hormuz disruptions tied to the Iran conflict. Market breadth has thinned sharply — only 33% of S&P 500 names trade above their 50-day moving average, down from 60%+ in late February. The VIX remains elevated near 20.
Against this volatility, we see opportunity. The AI capex cycle remains structurally intact — Morgan Stanley estimates $2.9T in global data center construction through 2028, accounting for roughly 25% of US GDP growth this year. And prediction markets are pricing several macro outcomes we believe the consensus has wrong. Here are this week’s highest-conviction plays.
The picks-and-shovels play on AI’s insatiable power demand. Q4 earnings crushed it — EPS of $13.39 beat estimates by 316%, revenue hit $11B. 2026 guidance of $44–45B revenue with $5–5.5B FCF is aggressive. The nuclear JV with Hitachi ($40B investment) positions them for the next decade of base-load demand. Rothschild just upgraded from Sell to Buy.
Clinical-stage oncology with a binary FDA catalyst. PDUFA date for zidesamtinib (ROS1-positive lung cancer) is September 18, 2026. This would be the company’s first approved product. Second NDA planned for H1 2026. $1.4B cash provides runway to 2029. 18 analysts rate it Strong Buy with an average target of $143.
BTC at $70,400 sits in the historically weakest phase of the 4-year cycle, but Citi’s bull case targets $165K. Stalled crypto legislation (passing odds slipped to ~60%) created the pullback. We’re dollar-cost averaging into weakness here — the structural case (ETF inflows, halving cycle, institutional adoption) hasn’t changed. Citi bear case is $58K, which we’d buy aggressively.
Polymarket prices 2+ rate cuts this year at just 43% implied probability. The market is fighting the last war on inflation. With oil-driven price spikes likely to fade in H2, GDP growth decelerating to 1–2%, and the labor market softening, we think the Fed cuts at least twice. The tariff cliff in mid-July adds another deflationary impulse. Buy YES on 2+ cuts.
Polymarket prices recession probability at 31%. While growth is slowing, the AI capex boom is contributing ~25% of GDP growth. Tax refunds and data center buildout likely keep H1 above 3%. A technical recession requires two consecutive quarters of contraction — the math doesn’t work unless oil goes to $130+ and stays there. Sell the fear.
Every Sunday, subscribers get fresh signals like these — actionable trade ideas across stocks, crypto & prediction markets with full thesis and risk analysis.
Subscribe for $29/mo →Cancel anytime. Secure checkout via Stripe.
Compound provides trade ideas for informational and educational purposes only. We are not registered investment advisors. Past performance does not guarantee future results. All trade ideas involve risk of loss. Always do your own research.